Literature DB >> 11278272

Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein.

T Vincent1, M Jourdan, M S Sy, B Klein, N Mechti.   

Abstract

Originating from a post-switch memory B cell or plasma cell compartment in peripheral lymphoid tissues, malignant myeloma cells accumulate in the bone marrow of patients with multiple myeloma. In this favorable microenvironment their growth and survival are dependent upon both soluble factors and physical cell-to-cell and cell-to-extracellular matrix contacts. In this report we show that hyaluronan (HA), a major nonprotein glycosaminoglycan component of the extracellular matrix in mammalian bone marrow, is a survival and proliferation factor for human myeloma cells. The effect of HA is mainly mediated through a gp 80-interleukin 6 (IL-6) receptor pathway by a CD44-independent mechanism, suggesting that HA retains and concentrates IL-6 close to its site of secretion, thus favoring its autocrine activity. In addition, we show that HA-mediated survival and proliferation of myeloma cells is associated with a down-regulation in the expression of p27(kip1) cyclin-dependent kinase inhibitor and a hyperphosphorylation of the retinoblastoma protein (pRb). These data suggest that HA could be an important component in the myeloma cell physiopathology in vivo by potentiating autocrine and/or paracrine IL-6 activities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278272     DOI: 10.1074/jbc.M003965200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy.

Authors:  Susan N Thomas; Nathan A Rohner; Erin E Edwards
Journal:  Annu Rev Biomed Eng       Date:  2016-02-24       Impact factor: 9.590

Review 2.  Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.

Authors:  Arun Balakumaran; Pamela Gehron Robey; Neal Fedarko; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2010-05       Impact factor: 5.225

Review 3.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

Review 4.  Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Drug Resist Updat       Date:  2008-05-19       Impact factor: 18.500

Review 5.  Molecular aspects of multiple myeloma.

Authors:  G Pratt
Journal:  Mol Pathol       Date:  2002-10

6.  Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation.

Authors:  Lei Ying; Anne B Hofseth; Darren D Browning; Mitzi Nagarkatti; Prakash S Nagarkatti; Lorne J Hofseth
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

7.  Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice.

Authors:  Melanie A Simpson; Christopher M Wilson; James B McCarthy
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

8.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

9.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

Review 10.  Targeting hyaluronic acid family for cancer chemoprevention and therapy.

Authors:  Vinata B Lokeshwar; Summan Mirza; Andre Jordan
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.